[go: up one dir, main page]

MX2023013665A - Polipeptidos del sars-cov-2. - Google Patents

Polipeptidos del sars-cov-2.

Info

Publication number
MX2023013665A
MX2023013665A MX2023013665A MX2023013665A MX2023013665A MX 2023013665 A MX2023013665 A MX 2023013665A MX 2023013665 A MX2023013665 A MX 2023013665A MX 2023013665 A MX2023013665 A MX 2023013665A MX 2023013665 A MX2023013665 A MX 2023013665A
Authority
MX
Mexico
Prior art keywords
cov
sars
polypeptides
document provides
coronavirus
Prior art date
Application number
MX2023013665A
Other languages
English (en)
Inventor
Gregory A Poland
Inna G Ovsyannikova
Richard B Kennedy
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of MX2023013665A publication Critical patent/MX2023013665A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Este documento proporciona métodos y materiales relacionados con polipéptidos del coronavirus 2 con dificultad respiratoria aguda grave (SARS-CoV-2) seleccionados. Por ejemplo, este documento proporciona composiciones de vacunas que contienen uno o más polipéptidos del SARS-CoV-2 seleccionados proporcionados en la presente y que tienen la capacidad de inducir o aumentar las respuestas inmunitarias contra coronavirus, tales como el SARS-CoV-2 en un mamífero (por ejemplo, un ser humano).
MX2023013665A 2021-05-20 2022-05-19 Polipeptidos del sars-cov-2. MX2023013665A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163190964P 2021-05-20 2021-05-20
US202263341771P 2022-05-13 2022-05-13
PCT/US2022/030068 WO2022246084A1 (en) 2021-05-20 2022-05-19 Sars-cov-2 polypeptides

Publications (1)

Publication Number Publication Date
MX2023013665A true MX2023013665A (es) 2024-01-08

Family

ID=82321637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013665A MX2023013665A (es) 2021-05-20 2022-05-19 Polipeptidos del sars-cov-2.

Country Status (10)

Country Link
US (1) US20220370601A1 (es)
EP (1) EP4294440A1 (es)
JP (1) JP2024521098A (es)
KR (1) KR20240012394A (es)
AU (1) AU2022277697A1 (es)
BR (1) BR112023024034A2 (es)
CA (1) CA3212678A1 (es)
IL (1) IL308465A (es)
MX (1) MX2023013665A (es)
WO (1) WO2022246084A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240042070A1 (en) * 2022-06-28 2024-02-08 Transcode Therapeutics, Inc. Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4138876A1 (en) * 2020-04-23 2023-03-01 ISA Pharmaceuticals B.V. Immunization against sars-cov-related diseases
GB202011652D0 (en) * 2020-07-28 2020-09-09 Univ Oxford Innovation Ltd Polypeptide panels and uses thereof
US11191827B1 (en) * 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19

Also Published As

Publication number Publication date
WO2022246084A1 (en) 2022-11-24
JP2024521098A (ja) 2024-05-28
BR112023024034A2 (pt) 2024-02-06
CA3212678A1 (en) 2022-11-24
AU2022277697A1 (en) 2024-01-04
IL308465A (en) 2024-01-01
EP4294440A1 (en) 2023-12-27
US20220370601A1 (en) 2022-11-24
KR20240012394A (ko) 2024-01-29

Similar Documents

Publication Publication Date Title
PH12020551261A1 (en) Il-15 conjugates and uses thereof
PH12020550051A1 (en) Glp-1 compositions and uses thereof
CL2018001845A1 (es) Moduladores de la 5'-nucleotidasa, ecto y su uso
MX2019008413A (es) Celulas pluripotentes inmunodiseñadas.
CY1126152T1 (el) Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων
MX2022003689A (es) Metodos y composiciones para el tratamiento contra una enfermedad o trastorno.
PH12022550510A1 (en) Conjugated hepcidin mimetics
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
MX2020009733A (es) Composiciones.
MY150829A (en) Oral compositions containing extracts of myristica fragrans and related methods
IL289932A (en) History of 6,3-diamino-pyridazin-3-yl, pharmaceutical preparations containing them and their use as pro-apoptotic agents
WO2018189661A3 (en) Methods and compounds for treating diabetes
CY1124010T1 (el) Μια φαρμακευτικη συνθεση για την παρεμποδιση της διατροφικης παχυσαρκιας
MX2023008333A (es) Nanomateriales.
MX2020012800A (es) Cannabinoides y usos de los mismos.
EA201891337A3 (ru) Фармацевтическая композиция от нейропатической боли
MX2023013665A (es) Polipeptidos del sars-cov-2.
EA200600439A1 (ru) 4- ((феноксиалкил)тио) феноксиуксусные кислоты и аналоги
MX2022007446A (es) Formulaciones dietéticas.
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
PH12020550104A1 (en) Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
PH12019550035A1 (en) The beta-caseins and gut microbiota
MY186286A (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease